MA41887B1 - Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci - Google Patents

Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Info

Publication number
MA41887B1
MA41887B1 MA41887A MA41887A MA41887B1 MA 41887 B1 MA41887 B1 MA 41887B1 MA 41887 A MA41887 A MA 41887A MA 41887 A MA41887 A MA 41887A MA 41887 B1 MA41887 B1 MA 41887B1
Authority
MA
Morocco
Prior art keywords
long
composition
glucagon derivative
acting conjugate
glucagon
Prior art date
Application number
MA41887A
Other languages
English (en)
Other versions
MA41887A1 (fr
Inventor
Sung Youb Jung
In Young Choi
Jung Kuk Kim
Young Jin Park
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA41887A1 publication Critical patent/MA41887A1/fr
Publication of MA41887B1 publication Critical patent/MA41887B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un dérivé de glucagon, un conjugué de glucagon à action prolongée du dérivé de glucagon, une utilisation de ceux-ci.
MA41887A 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci MA41887B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150093265 2015-06-30
PCT/KR2016/006984 WO2017003191A1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Publications (2)

Publication Number Publication Date
MA41887A1 MA41887A1 (fr) 2018-12-31
MA41887B1 true MA41887B1 (fr) 2020-05-29

Family

ID=57608802

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41887A MA41887B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
MA49545A MA49545B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA49545A MA49545B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Country Status (31)

Country Link
US (3) US10696725B2 (fr)
EP (2) EP4324519A2 (fr)
JP (3) JP6882210B2 (fr)
KR (2) KR102005456B1 (fr)
CN (1) CN108025041A (fr)
AR (1) AR105485A1 (fr)
AU (2) AU2016287209B2 (fr)
BR (1) BR112017028517A2 (fr)
CA (1) CA2991107A1 (fr)
CL (5) CL2017003402A1 (fr)
CO (1) CO2018000303A2 (fr)
CR (1) CR20180034A (fr)
DK (1) DK3322437T3 (fr)
DO (1) DOP2017000318A (fr)
EA (1) EA201890058A1 (fr)
EC (1) ECSP18003879A (fr)
FI (1) FI3322437T3 (fr)
HK (1) HK1248129A1 (fr)
IL (2) IL256619B (fr)
MA (2) MA41887B1 (fr)
MX (1) MX2017016845A (fr)
NZ (1) NZ739250A (fr)
PE (2) PE20240215A1 (fr)
PH (1) PH12017502393A1 (fr)
PL (1) PL3322437T3 (fr)
PT (1) PT3322437T (fr)
TN (1) TN2017000555A1 (fr)
TW (1) TWI713541B (fr)
UA (1) UA127445C2 (fr)
UY (1) UY36759A (fr)
WO (1) WO2017003191A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015185640A1 (fr) 2014-06-04 2015-12-10 Novo Nordisk A/S Co-agonistes de récepteur du glucagon/glp-1 à usage médical
CA2972748A1 (fr) * 2014-12-30 2016-07-07 Hanmi Pharm. Co., Ltd. Derive du glucagon a stabilite amelioree
DK3322437T3 (da) 2015-06-30 2024-03-25 Hanmi Pharmaceutical Co Ltd Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EA038544B1 (ru) 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Тройной агонист рецепторов глюкагона/glp-1/gip
IL263934B2 (en) 2016-06-29 2023-10-01 Hanmi Pharm Ind Co Ltd A derivative of glucagon, its conjugate, a preparation containing it and its medical use
AU2018215840A1 (en) * 2017-02-03 2019-08-01 Hanmi Pharm. Co., Ltd. Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof
KR20180091773A (ko) 2017-02-07 2018-08-16 한미약품 주식회사 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
US20200283492A1 (en) * 2017-09-29 2020-09-10 Hanmi Pharm Co., Ltd. Long acting protein complex having an enhanced efficiency
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
WO2020017919A1 (fr) * 2018-07-19 2020-01-23 한미정밀화학주식회사 Nouvel intermédiaire utilisé pour un polypeptide physiologiquement actif et son procédé de préparation
EP3823659A4 (fr) * 2018-07-19 2022-06-22 D&D Pharmatech Inc. Composition pharmaceutique comprenant un polypeptide
CA3115193A1 (fr) * 2018-10-04 2020-04-09 Hanmi Pharm. Co., Ltd. Utilisations therapeutiques du glucagon et produit combine comprenant celui-ci
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
JP2022514835A (ja) * 2018-12-21 2022-02-16 ハンミ ファーマシューティカル カンパニー リミテッド インスリン及びグルカゴンを含む薬学組成物
EP4311578A3 (fr) * 2019-06-28 2024-04-10 Hanmi Pharm. Co., Ltd. Triple agoniste ayant une activité par rapport à tous les récepteurs du glucagon, de glp-1 et de gip pour traitement de maladies hépathiques
US20230000950A1 (en) * 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
US20210290732A1 (en) * 2020-02-21 2021-09-23 Spitfire Pharma Llc GLP-1R and GCGR Agonists, Formulations, and Methods of Use
JP2023526551A (ja) * 2020-05-22 2023-06-21 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体の持続型結合体の液状製剤
US20230310631A1 (en) * 2020-07-15 2023-10-05 Hanmi Pharm. Co., Ltd. Therapeutic use of glucagon derivative or conjugate thereof for liver disease
AU2021326369A1 (en) * 2020-08-14 2023-02-23 Hanmi Pharm. Co., Ltd. Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, GLP-1, and GIP receptors
IL305549A (en) * 2021-04-09 2023-10-01 Hanmi Pharm Ind Co Ltd Pharmaceutical composition for the prevention or treatment of chronic kidney disease including a glucagon derivative
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP1411968B1 (fr) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1, exendine-4, analogues peptidiques et utilisations associees
BRPI0407936A (pt) 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
AU2004282984B2 (en) * 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2158214B1 (fr) 2007-06-15 2011-08-17 Zealand Pharma A/S Analogues du glucagon
CA2696615A1 (fr) 2007-06-19 2008-12-24 Otsuka Chemical Co., Ltd. Peptide glp-1 ayant une chaine de sucres liee a celui-ci
EP2679597A1 (fr) 2007-09-05 2014-01-01 Novo Nordisk A/S Dérivés de peptide 1 de type glucagon et leur utilisation pharmaceutique
WO2009099763A1 (fr) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d’esters
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
JP6108659B2 (ja) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
WO2010096052A1 (fr) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
EA022816B1 (ru) * 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2512503A4 (fr) * 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Co-agonistes du récepteur du glucagon/glp-i
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
RU2559320C2 (ru) * 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
ES2713952T3 (es) 2010-12-22 2019-05-24 Univ Indiana Res & Tech Corp Análogos de glucagón que muestran actividad de receptor de GIP
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
EP2710031B9 (fr) 2011-05-18 2018-02-28 Mederis Diabetes, LLC Substances pharmaceutiques peptidiques améliorées pour la résistance à l'insuline
ES2692187T3 (es) * 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
EP2721062B1 (fr) 2011-06-17 2018-11-14 Hanmi Science Co., Ltd. Conjugué comprenant de l'oxyntomoduline et un fragment d'immunoglobuline, et son utilisation
WO2013004983A1 (fr) 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
CN103957927B (zh) 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
EP2817025A2 (fr) 2012-02-08 2014-12-31 Seneb Biosciences, Inc. Traitement de l'hypoglycémie
WO2013170636A1 (fr) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 Protéine et conjugué protéique pour le traitement du diabète et applications associées
EP2864351B1 (fr) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
WO2013192130A1 (fr) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
ES2748158T3 (es) * 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
EP3444281B1 (fr) 2012-11-20 2021-11-03 Eumederis Pharmaceuticals, Inc. Produits pharmaceutiques de peptides améliorés
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
WO2015022420A1 (fr) 2013-08-16 2015-02-19 Medimmune Limited Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
US20160137712A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion Proteins With Dual Receptor Agonist Activities
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
CA2972748A1 (fr) * 2014-12-30 2016-07-07 Hanmi Pharm. Co., Ltd. Derive du glucagon a stabilite amelioree
DK3322437T3 (da) 2015-06-30 2024-03-25 Hanmi Pharmaceutical Co Ltd Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
US20170004368A1 (en) 2015-07-05 2017-01-05 Neteera Technologies Ltd. System and method for biometric detection based on sweat ducts
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
CN109069569B (zh) 2015-12-02 2023-02-14 韩美药品株式会社 使用脂肪酸衍生物的蛋白缀合物及其制备方法
EA038544B1 (ru) 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Тройной агонист рецепторов глюкагона/glp-1/gip

Also Published As

Publication number Publication date
EP3322437B1 (fr) 2024-01-17
EP3322437A1 (fr) 2018-05-23
AR105485A1 (es) 2017-10-11
JP2023062043A (ja) 2023-05-02
US20180186853A1 (en) 2018-07-05
EP4324519A2 (fr) 2024-02-21
CA2991107A1 (fr) 2017-01-05
PE20180449A1 (es) 2018-03-05
KR20190092343A (ko) 2019-08-07
EA201890058A1 (ru) 2018-07-31
CL2023001911A1 (es) 2023-11-17
AU2016287209B2 (en) 2023-03-02
PL3322437T3 (pl) 2024-05-20
PH12017502393A1 (en) 2018-06-25
JP2018526333A (ja) 2018-09-13
MA49545B1 (fr) 2022-03-31
CN108025041A (zh) 2018-05-11
MA41887A1 (fr) 2018-12-31
US11667688B2 (en) 2023-06-06
IL256619A (en) 2018-04-30
US11261227B2 (en) 2022-03-01
KR102395855B1 (ko) 2022-05-10
HK1248129A1 (zh) 2018-10-12
US20200223897A1 (en) 2020-07-16
TW201713681A (zh) 2017-04-16
CL2023001910A1 (es) 2023-11-17
AU2016287209A1 (en) 2018-02-15
EP3322437A4 (fr) 2019-10-09
BR112017028517A2 (pt) 2018-08-28
US20220127325A1 (en) 2022-04-28
TN2017000555A1 (en) 2019-04-12
UA127445C2 (uk) 2023-08-30
IL291291A (en) 2022-05-01
CL2023001909A1 (es) 2023-11-17
MX2017016845A (es) 2018-08-01
NZ739250A (en) 2024-02-23
KR102005456B1 (ko) 2019-07-30
IL291291B2 (en) 2023-06-01
CR20180034A (es) 2018-04-16
CL2017003402A1 (es) 2018-04-20
US10696725B2 (en) 2020-06-30
JP6882210B2 (ja) 2021-06-02
TWI713541B (zh) 2020-12-21
WO2017003191A1 (fr) 2017-01-05
JP2021102618A (ja) 2021-07-15
PT3322437T (pt) 2024-03-20
DOP2017000318A (es) 2018-04-30
CO2018000303A2 (es) 2018-07-10
IL256619B (en) 2022-04-01
AU2023201118A1 (en) 2023-04-20
CL2023000198A1 (es) 2023-06-30
FI3322437T3 (fi) 2024-02-20
MA49545A1 (fr) 2021-09-30
PE20240215A1 (es) 2024-02-16
DK3322437T3 (da) 2024-03-25
UY36759A (es) 2017-01-31
KR20170003466A (ko) 2017-01-09
ECSP18003879A (es) 2018-03-31

Similar Documents

Publication Publication Date Title
MA41887A1 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
CR20160419A (es) Nuevos compuestos biciclicos
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201992177A1 (ru) Композиции на основе нирапариба
CL2019003599S1 (es) Extintor.
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
MA45857A (fr) Composés et compositions, et utilisations associées
MA45795A (fr) Composés et compositions, et utilisations associées
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
FR3056590B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
CL2019002372S1 (es) Portalón.
ES1241151Y (es) Multi-colmena.
CL2018003014S1 (es) Cápsula.
IT201700080501A1 (it) Riduttore.
MA42889B2 (fr) Triple activateur activant le récepteur du glucagon, du glp-1 et du gip
EA201792492A1 (ru) Aml-антигены и их применение
FR3056586B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056585B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056587B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056589B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6